Session » Epidemiology and Public Health Poster I: Rheumatoid Arthritis

Date: Sunday, October 21, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 215

A Decade Earlier- Onset of Symptoms of RA in the Indian (Asian) Cohort Compared to Dutch Cohort: Based on Meteor, a Global Database

9:00AM-11:00AM: Abstract Number: 208

Antibodies to Citrullinated Protein Antigens Are Associated with Risk of Cardiovascular Disease in Community-Dwelling Women: The Multi-Ethnic Study of Atherosclerosis

9:00AM-11:00AM: Abstract Number: 217

Association between Comorbidities and Socioeconomic Status Among Patients with Rheumatoid Arthritis in Korea

9:00AM-11:00AM: Abstract Number: 210

Changes in Alcohol Use in Patients with Rheumatoid Arthritis: Associations with Disease Activity, Health Status, and Mortality

9:00AM-11:00AM: Abstract Number: 205

Circulating Plasma Metabolites and Risk of Rheumatoid Arthritis in the Nurses Health Study

9:00AM-11:00AM: Abstract Number: 235

Clinical Predictors and Risk of Methotrexate Induced Liver Fibrosis

9:00AM-11:00AM: Abstract Number: 209

Development of an Algorithm for the Classification of Cardiovascular Comorbidity in Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative

9:00AM-11:00AM: Abstract Number: 229

Disability Status, Mortality, and Leading Causes of Death in Seropositive Rheumatoid Arthritis Patients: A Population-Based Study in Korea

9:00AM-11:00AM: Abstract Number: 221

Distal Interphalangeal Joint Involvement and Its Association with Disease Activity in Rheumatoid Arthritis (RA): Analysis Based on a Nationwide RA Database in Japan

9:00AM-11:00AM: Abstract Number: 207

Divergent Patterns of Cardiovascular Risk in Biomarkers of Lipids and Subclinical Myocardial Injury during Increased Inflammation in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 211

Excess in Prevalence of Functional Disability in Patients with Rheumatoid Arthritis: Does Serologic Status Matter?

9:00AM-11:00AM: Abstract Number: 213

Excessive Risk of Major Cardiovascular Events in Sero-Positive Rheumatoid Arthritis and in Patients with Active Disease

9:00AM-11:00AM: Abstract Number: 214

Exploring the Relation between Air Pollution and Disease Activity in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 236

Hypogammaglobulinemia and Infection Risk in Patients Treated with Rituximab

9:00AM-11:00AM: Abstract Number: 238

IL Inhibitors Therapy in Rheumatic Diseases and the Risk of Malignancies: Systematic Review and Meta-Analysis of Rare Harmful Effects in Randomized Controlled Trials

9:00AM-11:00AM: Abstract Number: 206

Impact of International Classification of Diseases 10th Revision Codes and Updated Medical Information on an Existing Rheumatoid Arthritis Phenotype Algorithm Using Electronic Medical Data

9:00AM-11:00AM: Abstract Number: 219

Impact of Rheumatoid Arthritis on Influenza-Related Complications: A Population Based Cohort Study

9:00AM-11:00AM: Abstract Number: 230

Increased Prevalence of Coronary Artery Disease in Patients with Chest Pain and Seropositive Rheumatoid Arthritis: An Analysis from a Clinical Computed Tomography-Based Large-Scale Population Cohort

9:00AM-11:00AM: Abstract Number: 216

Inflectra and Remicade Use and Cost in Canada Under Provincial Drug Plans in 2016

9:00AM-11:00AM: Abstract Number: 232

Inpatient Mortality in Transition-Aged Youth with Rheumatic Disease: An Analysis of the National Inpatient Sample

9:00AM-11:00AM: Abstract Number: 204

Investigating Asthma, Allergic Disease, Passive Smoke Exposure, and Risk of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 203

Meat Consumption and Risk of Rheumatoid Arthritis in Women: A Population-Based Cohort Study

9:00AM-11:00AM: Abstract Number: 212

Mortality and Causes of Death in Patients with Inflammatory Arthritis in Hong Kong over 20 Years

9:00AM-11:00AM: Abstract Number: 220

Non-Medical Switch to Biosimilars: What Have We Learned?

9:00AM-11:00AM: Abstract Number: 201

Occupational Exposure to Coal and Silica Dust Is Associated with Elevated Risk of Rheumatoid Arthritis in Coal Mining Areas of US

9:00AM-11:00AM: Abstract Number: 239

Outcomes of Hospitalizations and the Temporal Trends in Mortality from Acute Myocardial Infarction in Patients with RA and FM during 2005 to 2015

9:00AM-11:00AM: Abstract Number: 234

Population-Based Estimates of Fatigue Prevalence Among Adults Aged >18 Years with and without Arthritis, United States, 2015-2016

9:00AM-11:00AM: Abstract Number: 231

Rates of Influenza Vaccination in a Cohort of Patients with Rheumatoid Arthritis and Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 226

Representation of Elderly People and Women in Rheumatoid Arthritis and Osteoarthritis Trials: A Systematic Review and Meta-Analysis Comparing Clinical Trials with Population-Based Studies

9:00AM-11:00AM: Abstract Number: 227

Rheumatoid Arthritis Patients Treated with Abatacept, Rituximab and Tocilizumab in Denmark and Sweden: Risk of Serious Infections

9:00AM-11:00AM: Abstract Number: 202

Risk of Inflammatory Arthritis Development in the Family Members of Indigenous North American (INA) RA Patients

9:00AM-11:00AM: Abstract Number: 218

Risk of Serious Infection Associated with TNF Inhibitor Versus Triple Therapy in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 224

Risk of Venous Thrombotic Events in Rheumatoid Arthritis Patients Initiating Tofacitinib or Adalimumab

9:00AM-11:00AM: Abstract Number: 223

The Effect of Concomitant Diabetes on RA-Related Outcomes: Results from the Acr’s RISE Registry

9:00AM-11:00AM: Abstract Number: 237

The Risk of Serious and Opportunistic Infections in Rheumatologic Patients on Interleukin Inhibitors: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 233

TNF Inhibitors: Prevalence of Use and Predictors of Treatment Non-Persistence in the 2011-2016 Medicare Population

9:00AM-11:00AM: Abstract Number: 225

U.S. Trends in Hospitalization Rates and Causes and in-Hospital Mortality in Rheumatoid Arthritis Patients, 2000-2014

9:00AM-11:00AM: Abstract Number: 200

Validation of the Ers-RA Risk Score in a Dutch Population

9:00AM-11:00AM: Abstract Number: 222

Viral Exposures As a Risk Factor for Rheumatoid Arthritis: Summarizing the Evidence

9:00AM-11:00AM: Abstract Number: 228

Widespread Chronic Use of Proton-Pump Inhibitors and Potential for Drug-Drug Interactions in Rheumatoid Arthritis and Lupus Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].